Shots:
- The Chinese NMPA has approved Nucala as an add-on maintenance treatment of adults with inadequately controlled COPD characterised by eosinophilic phenotype based on the P-III (MATINEE & METREX) trial; EMA filing is under review
- MATINEE assessed Nucala (100mg, SC, Q4W) vs PBO in COPD pts (n=804) with type 2 inflammation while METREX evaluated it vs PBO in 836 pts across eosinophilic & non-eosinophilic phenotype group for 52wks.
- Both trials showed reduced annualized mod. or sev. exacerbation rates in the eosinophilic phenotype with added triple inhaled therapy while in MATINEE, Nucala also lowered COPD exacerbations requiring ED visits &/or hospitalization (2EP)
Ref: GSK | Image: GSK | Press Release
Related News: GSK Reports the FDA Approval of Exdensur (Depemokimab-ulaa) for Asthma with Eosinophilic Phenotype
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
